Paratek Pharmaceuticals Management
Paratek Pharmaceuticals employs about 268 people. The company is managed by 9 executives with a total tenure of roughly 22 years, averaging almost 2.0 years of service per executive, having 29.78 employees per reported executive. Inspection of Paratek Pharmaceuticals' management performance can provide insight into the company performance.
| William Haskel President Senior Vice President General Counsel, Corporate Secretary |
| Adam Woodrow President Vice President and Chief Commercial Officer |
Paratek |
Paratek Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.1799) % which means that it has lost $0.1799 on every $100 spent on assets. This is way below average. Paratek Pharmaceuticals' management efficiency ratios could be used to measure how well Paratek Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Paratek Pharmaceuticals Workforce Comparison
Paratek Pharmaceuticals is regarded second in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 1,354. Paratek Pharmaceuticals retains roughly 268 in number of employees claiming about 20% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.35) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.25) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.25. Paratek Pharmaceuticals Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Paratek Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Paratek Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Paratek Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Adam Woodrow over a year ago Disposition of 622284 shares by Adam Woodrow of Paratek Pharmaceuticals subject to Rule 16b-3 | ||
Adam Woodrow over a year ago Acquisition by Adam Woodrow of 98750 shares of Paratek Pharmaceuticals subject to Rule 16b-3 | ||
Wortzman Marilyn E over a year ago Exercise or conversion by Wortzman Marilyn E of 4600 shares of Paratek Pharmaceuticals subject to Rule 16b-3 |
Paratek Pharmaceuticals Notable Stakeholders
A Paratek Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Paratek Pharmaceuticals often face trade-offs trying to please all of them. Paratek Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Paratek Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| William Haskel | Senior Vice President General Counsel, Corporate Secretary | Profile | |
| Adam Woodrow | Vice President and Chief Commercial Officer | Profile | |
| CPA CPA | Ex Chairman | Profile | |
| FACC FAHA | CEO Director | Profile | |
| Karen McGrath | VP HR | Profile | |
| Sarah Higgins | Interim Principal Financial Officer and Principal Accounting Officer | Profile | |
| Ben Strain | VP CEO | Profile | |
| Jason Burdette | VP Operations | Profile | |
| Randall Brenner | Chief Officer | Profile |
Paratek Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Paratek Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Paratek Pharmaceuticals within its industry.Paratek Pharmaceuticals Manpower Efficiency
Return on Paratek Pharmaceuticals Manpower
| Revenue Per Employee | 562.6K | |
| Revenue Per Executive | 16.8M | |
| Net Loss Per Employee | 237.2K | |
| Net Loss Per Executive | 7.1M | |
| Working Capital Per Employee | 371.1K | |
| Working Capital Per Executive | 11.1M |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Other Consideration for investing in Paratek Stock
If you are still planning to invest in Paratek Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Paratek Pharmaceuticals' history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |